Search

Coloplast A-S (Class B)

Ouvert

728.2 0.36

Résumé

Variation du prix de l'action

24h

Actuel

Min

724.8

Max

730.2

Chiffres clés

By Trading Economics

Revenu

-270M

1B

Ventes

73M

7B

P/E

Moyenne du Secteur

32.369

57.333

BPA

6.38

Rendement du dividende

3.13

Marge bénéficiaire

14.859

Employés

16,628

EBITDA

-42M

2.2B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.13%

2.63%

Prochains Résultats

6 mai 2025

Date du Prochain Dividende

14 mai 2025

Date du Prochain Détachement de Dividende

12 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

158B

Ouverture précédente

727.84

Clôture précédente

728.2

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 avr. 2025, 23:55 UTC

Market Talk

Oil Edges Higher Amid Hopes for Easing U.S.-China Trade Tensions -- Market Talk

27 avr. 2025, 23:47 UTC

Market Talk

Gold Falls Amid Dollar Strength, Signs of Easing U.S.-China Trade Tensions -- Market Talk

27 avr. 2025, 23:42 UTC

Market Talk

Nikkei May Rise as Fears About U.S.-China Tensions Ebb -- Market Talk

27 avr. 2025, 23:12 UTC

Résultats

Sinopharm Group 1Q Rev CNY141.66B Vs. CNY147.27B >1099.HK

27 avr. 2025, 23:12 UTC

Résultats

Sinopharm Group 1Q Net CNY1.46B Vs. Net CNY1.42B >1099.HK

27 avr. 2025, 20:41 UTC

Résultats

Pharmaron Beijing 1Q Net CNY305.58M Vs. Net CNY230.56M >300759.SZ

27 avr. 2025, 20:41 UTC

Résultats

Pharmaron Beijing: Higher Contributions From Laboratory Services Among Factors Supporting Results> 300759.SZ

27 avr. 2025, 20:41 UTC

Résultats

Pharmaron Beijing 1Q Rev CNY3.10B Vs. CNY2.67B >300759.SZ

27 avr. 2025, 18:41 UTC

Actualités

Bessent Doesn't Know If Trump and Xi Have Talked on Trade -- Barrons.com

27 avr. 2025, 11:00 UTC

Actualités

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

27 avr. 2025, 05:41 UTC

Résultats

China Everbright Bank 1Q Net CNY12.46B Vs. Net CNY12.43B >601818.SH

27 avr. 2025, 05:41 UTC

Résultats

China Everbright Bank: Lower Net Interest Income Weighed on Operating Income>601818.SH

27 avr. 2025, 05:41 UTC

Résultats

China Everbright Bank 1Q Operating Income CNY33.10B Vs. CNY34.49B>601818.SH

27 avr. 2025, 05:41 UTC

Résultats

China Everbright Bank 1Q Impairment Loss on Credit Assets Was CNY8.49B; Down 15.6% on Year>601818.SH

27 avr. 2025, 05:41 UTC

Résultats

China Everbright Bank 1Q Operating Expenses Was CNY9.15B; Down 3.2%>601818.SH

27 avr. 2025, 05:41 UTC

Résultats

China Everbright Bank 1Q Net Interst Income Was CNY22.54B; Down 6.8% on Year>601818.SH

27 avr. 2025, 05:34 UTC

Résultats

Chongqing Rural Commercial Bank: 1Q Results Supported by Higher Net Interest Income>3618.HK

27 avr. 2025, 05:34 UTC

Résultats

Chongqing Rural Commercial Bank 1Q Operating Income CNY7.22B Vs. CNY7.13B>3618.HK

27 avr. 2025, 05:34 UTC

Résultats

Chongqing Rural Commercial Bank 1Q Net CNY3.75B Vs. Net CNY3.52B >3618.HK

27 avr. 2025, 05:29 UTC

Résultats

China Shenhua Energy: Results Weighed by Fall in Selling Prices of Coal >1088.HK

27 avr. 2025, 05:29 UTC

Résultats

China Shenhua Energy 1Q Net CNY13.37B Vs. Net CNY17.76B >1088.HK

27 avr. 2025, 05:29 UTC

Résultats

China Shenhua Energy 1Q Rev CNY69.59B Vs. CNY87.65B >1088.HK

27 avr. 2025, 05:29 UTC

Résultats

China Shenhua Energy: Lower Revenue From Electricity Sales Also Hurt Results >1088.HK

27 avr. 2025, 05:21 UTC

Résultats

CMOC Group 1Q Net CNY3.95B Vs. Net CNY2.07B >3993.HK

27 avr. 2025, 05:21 UTC

Résultats

CMOC Group: Cost Cuts Also Among Factors that Boosted 1Q Net >3993.HK

27 avr. 2025, 05:21 UTC

Résultats

CMOC Group 1Q Rev CNY46.01B Vs. CNY46.12B >3993.HK

27 avr. 2025, 05:21 UTC

Résultats

CMOC Group: Increase in Prices of Copper, Cobalt Supported Results>3993.HK

27 avr. 2025, 03:00 UTC

Actualités

Chinese Manufacturers Are Scouring the World for New Buyers -- WSJ

27 avr. 2025, 00:30 UTC

Actualités

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ

27 avr. 2025, 00:30 UTC

Actualités

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ -2-

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.